The first stop for professional medicines advice

Understanding the characteristics of COVID-19 Vaccines

Published Last updated See all updates
Topics: COVID-19 vaccineService advice and planning

An introduction to the Understanding the characteristics of COVID-19 Vaccines pages

This article forms part of a series
  1. Understanding the characteristics of COVID-19 Vaccines
    1. Understanding the characteristics of Comirnaty 30 (XBB.1.5) vaccine
    2. Understanding the characteristics of Comirnaty 10 (XBB.1.5) ready to use vaccine
    3. Understanding the characteristics of Comirnaty 3 (THREE) (XBB.1.5) concentrate vaccine
    4. Understanding the characteristics of VidPrevtyn Beta
    5. Understanding the characteristics of Spikevax (XBB.1.5) vaccine

Overview

COVID-19 vaccines must be handled with care, and following the manufacturer’s instructions. This series of articles considers each COVID-19 vaccine in turn, outlining critical information and signposting the Summary of Product Characteristics. 

For guidance and example standard operating procures relating to the handling and preparation of COVID-19 vaccines, see our Managing Covid-19 Vaccines: Guidance and SOPs article. 

Update history

  1. Removed Comirnaty Original/Omicron BA 4/5, Comirnaty 10 Concentrate for children (5-11 years), Comirnaty 3 (THREE) concentrate and Spikevax Original/Omicron BA 4/5 from series
  1. Spikevax (XBB.1.5) and Comirnaty 3 (THREE) (XBB.1.5) vaccine added to series
  1. Comirnaty 10 (XBB.1.5) ready to use vaccine added to series
  1. Comirnaty 30 (XBB.1.5) vaccine added to series
  1. Updated with information regarding the Autumn 2023 campaign
  1. Added Comirnaty 3 (THREE) Concentrate
  1. Added Spikevax Original/Omicron BA.4-5
  1. Coming soon note added for Comirnaty 3 (THREE) Concentrate and Spikevax Original/Omicron BA.4-5
  1. Updated to cover vaccines used in the Spring 2023 campaign
  1. Nuvaxovid and Vaxzevria resources not provided by SPS. Statement added to clarify.
  1. Comirnaty 10 (XBB.1.5) ready to use vaccine added to series
  1. Published